C4 Therapeutics（纳斯达克代码：CCCC）宣布与罗氏集团达成战略拓展协议，双方将基于新型靶向蛋白降解技术平台，共同探索降解剂-抗体偶联物的开发路径。该合作标志着两家公司在肿瘤治疗领域长达数年的合作关系进入新阶段。
根据协议框架，C4 Therapeutics将获得预付款及阶段性研发里程碑资金，具体金额未公开。双方将整合C4T的专有蛋白降解技术与罗氏的抗体工程平台，致力于开发针对肿瘤特异性抗原的精准疗法。降解剂-抗体偶联物技术有望通过抗体介导的靶向递送系统，提升蛋白降解剂在病变组织的富集效率。
此次合作延续了双方自2020年以来的联合研发成果。此前共同开发的BRAF V600E蛋白降解剂CFT8919已进入临床研究阶段，展示出对非小细胞肺癌的潜在治疗价值。新协议将进一步拓展双方向血液肿瘤及实体瘤领域的联合探索。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.